Dr Reddy's Laboratories(DE:RDDA)
€13.20+0.00 (+3.13%)
DE:RDDA
Dr Reddy's Laboratories financials statements
€13.20
At close:+0.00 (+3.13%)
Dr Reddy's Laboratories (RDDA) Ratios
4 Followers
Dr Reddy's Laboratories Ratios
DE:RDDA's free cash flow for Q2 2027 was ₹2.31B. For the 2027 fiscal year, DE:RDDA's free cash flow was decreased by ₹-2.39B and operating cash flow was ₹4.69B. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.80 | 1.92 | 2.58 | 2.38 | 1.93 |
| Quick Ratio | 1.35 | 1.37 | 1.92 | 1.81 | 1.39 |
| Cash Ratio | 0.09 | 0.11 | 0.07 | 0.07 | 0.16 |
| Solvency Ratio | 0.34 | 0.47 | 0.66 | 0.64 | 0.35 |
| Operating Cash Flow Ratio | 0.34 | 0.36 | 0.47 | 0.69 | 0.30 |
| Short-Term Operating Cash Flow Coverage | 0.89 | 1.22 | 3.57 | 5.26 | 1.04 |
| Net Current Asset Value | ₹ 101.05B | ₹ 94.29B | ₹ 141.08B | ₹ 113.39B | ₹ 79.56B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.13 | 0.09 | 0.05 | 0.04 | 0.12 |
| Debt-to-Equity Ratio | 0.21 | 0.14 | 0.07 | 0.06 | 0.18 |
| Debt-to-Capital Ratio | 0.17 | 0.12 | 0.07 | 0.06 | 0.15 |
| Long-Term Debt-to-Capital Ratio | 0.03 | 0.01 | 0.01 | 0.00 | 0.02 |
| Financial Leverage Ratio | 1.54 | 1.48 | 1.38 | 1.39 | 1.54 |
| Debt Service Coverage Ratio | 1.04 | 1.89 | 5.00 | 4.69 | 1.30 |
| Interest Coverage Ratio | 12.42 | 25.40 | 39.58 | 40.02 | 30.77 |
| Debt to Market Cap | 0.07 | 0.04 | 0.02 | 0.01 | 0.04 |
| Interest Debt Per Share | 95.80 | 59.52 | 26.07 | 17.95 | 41.96 |
| Net Debt to EBITDA | 0.73 | 0.33 | 0.15 | 0.10 | 0.42 |
| Profitability Margins | |||||
| Gross Profit Margin | 52.77% | 58.50% | 58.61% | 56.67% | 53.10% |
| EBIT Margin | 17.43% | 24.46% | 26.36% | 25.13% | 15.51% |
| EBITDA Margin | 23.56% | 29.70% | 31.67% | 30.27% | 21.03% |
| Operating Profit Margin | 13.83% | 22.07% | 24.26% | 23.24% | 13.75% |
| Pretax Profit Margin | 16.32% | 23.59% | 25.74% | 24.55% | 15.06% |
| Net Profit Margin | 12.76% | 17.37% | 19.95% | 18.33% | 10.99% |
| Continuous Operations Profit Margin | 12.64% | 17.58% | 19.95% | 18.33% | 10.99% |
| Net Income Per EBT | 78.17% | 73.64% | 77.48% | 74.66% | 72.97% |
| EBT Per EBIT | 118.03% | 106.88% | 106.11% | 105.64% | 109.57% |
| Return on Assets (ROA) | 7.94% | 11.47% | 14.37% | 14.00% | 8.05% |
| Return on Equity (ROE) | 12.20% | 16.96% | 19.85% | 19.51% | 12.37% |
| Return on Capital Employed (ROCE) | 12.11% | 19.81% | 23.24% | 24.21% | 14.83% |
| Return on Invested Capital (ROIC) | 8.10% | 13.34% | 17.18% | 17.19% | 9.48% |
| Return on Tangible Assets | 9.97% | 14.71% | 16.08% | 15.72% | 9.02% |
| Earnings Yield | 4.19% | 6.01% | 5.42% | 5.80% | 3.35% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.56 | 2.97 | 2.93 | 2.96 | 2.67 |
| Payables Turnover | 5.10 | 6.74 | 5.36 | 5.97 | 6.30 |
| Inventory Turnover | 2.23 | 1.90 | 1.82 | 2.19 | 1.98 |
| Fixed Asset Turnover | 3.11 | 3.33 | 3.63 | 3.70 | 3.45 |
| Asset Turnover | 0.62 | 0.66 | 0.72 | 0.76 | 0.73 |
| Working Capital Turnover Ratio | 2.81 | 2.40 | 2.06 | 2.38 | 4.83 |
| Cash Conversion Cycle | 194.86 | 260.97 | 257.33 | 229.08 | 263.39 |
| Days of Sales Outstanding | 102.45 | 123.10 | 124.65 | 123.51 | 136.66 |
| Days of Inventory Outstanding | 164.00 | 192.04 | 200.74 | 166.75 | 184.71 |
| Days of Payables Outstanding | 71.60 | 54.17 | 68.06 | 61.18 | 57.97 |
| Operating Cycle | 266.45 | 315.14 | 325.39 | 290.26 | 321.37 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 68.05 | 55.71 | 54.51 | 70.92 | 33.89 |
| Free Cash Flow Per Share | 38.57 | 14.44 | 21.59 | 48.19 | 10.92 |
| Dividend Paid and CapEx Coverage Ratio | 1.80 | 1.13 | 1.33 | 2.47 | 1.21 |
| Capital Expenditure Coverage Ratio | 2.31 | 1.35 | 1.66 | 3.12 | 1.48 |
| Operating Cash Flow Coverage Ratio | 0.75 | 0.99 | 2.27 | 4.37 | 0.83 |
| Operating Cash Flow to Sales Ratio | 0.16 | 0.14 | 0.16 | 0.24 | 0.13 |
| Free Cash Flow Yield | 2.98% | 1.28% | 1.75% | 5.15% | 1.29% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 24.00 | 16.63 | 18.45 | 17.24 | 29.85 |
| Price-to-Sales (P/S) Ratio | 3.05 | 2.89 | 3.68 | 3.16 | 3.28 |
| Price-to-Book (P/B) Ratio | 2.91 | 2.82 | 3.66 | 3.36 | 3.69 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 33.56 | 78.16 | 57.08 | 19.41 | 77.66 |
| Price-to-Operating Cash Flow Ratio | 19.02 | 20.25 | 22.61 | 13.19 | 25.03 |
| Price-to-Earnings Growth (PEG) Ratio | -1.17 | 10.58 | 0.80 | 0.19 | 0.81 |
| Enterprise Value Multiple | 13.66 | 10.06 | 11.76 | 10.54 | 16.03 |
| Enterprise Value | 1.14T | 972.37B | 1.04T | 784.44B | 722.51B |
| EV to EBITDA | 13.66 | 10.06 | 11.76 | 10.54 | 16.03 |
| EV to Sales | 3.22 | 2.99 | 3.73 | 3.19 | 3.37 |
| EV to Free Cash Flow | 35.45 | 80.83 | 57.79 | 19.61 | 79.76 |
| EV to Operating Cash Flow | 20.09 | 20.94 | 22.90 | 13.32 | 25.70 |
| Tangible Book Value Per Share | 309.11 | 274.27 | 287.14 | 235.97 | 191.54 |
| Shareholders’ Equity Per Share | 444.01 | 400.07 | 336.58 | 278.24 | 229.71 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.23 | 0.25 | 0.23 | 0.25 | 0.27 |
| Revenue Per Share | 424.64 | 390.65 | 334.91 | 296.18 | 258.49 |
| Net Income Per Share | 54.16 | 67.85 | 66.80 | 54.29 | 28.42 |
| Tax Burden | 0.78 | 0.74 | 0.77 | 0.75 | 0.73 |
| Interest Burden | 0.94 | 0.96 | 0.98 | 0.98 | 0.97 |
| Research & Development to Revenue | 0.07 | 0.08 | 0.08 | 0.08 | 0.08 |
| SG&A to Revenue | 0.32 | 0.29 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.26 | 0.81 | 0.82 | 1.31 | 1.19 |
Currency in INR
